

<b>Pre-Program Activities</b>	<b>Pre-Lecture 1 – Viral Hepatitis</b> –A summary for discovery and natural history of HCV 60 min <b>Pre-Lecture 2 - End Stage Liver Disease:</b> An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min
<b>7:30 am</b>	<b>Registration and View Exhibits</b>
<b>8:00 am</b>	<b>Opening Comments and Pre-Test</b>
<b>8:20 am</b>	<b>Advances in the Screening and Treatment of HCV</b> <ul style="list-style-type: none"> <li>• Highlight of Pre-Lecture 1</li> <li>• Updates on diagnostic approaches</li> <li>• Screening and Treatment of HCV</li> <li>• Caring for At-risk populations – homeless, PWID, the incarcerated</li> <li>• Novel FDA Approved Direct Acting Anti-virals</li> <li>• Clinical Cases and Discussion</li> </ul>
<b>9:10 am</b>	<b>Hepatitis B: Epidemiology, Natural History, Testing and Treatment</b> <ul style="list-style-type: none"> <li>• The epidemiology of the Hepatitis B infection</li> <li>• Efficacies and opportunities in HBV testing and vaccination</li> <li>• Disease progression and impact on liver health</li> <li>• The efficacy of HBV Vaccination</li> <li>• Anti-viral therapies of HBV</li> <li>• The growing relationship between HBV and HDV</li> <li>• HBV Re-activation</li> <li>• Latest studies from EASL and AASLD</li> </ul>
<b>9:40 am</b>	<b>Delta Hepatitis and Hepatitis E Update</b> <ul style="list-style-type: none"> <li>• Global and US perspective on the growth of Delta Hepatitis</li> <li>• Lonafarnib and Bulevirtide of HDV: Benefits and potential hazards</li> <li>• Testing and surveillance approaches</li> <li>• Real world outcome studies on HDV and HEV</li> <li>• Management of Chronic HEV</li> </ul>
<b>10:15 am</b>	<b>Break and View exhibits</b>
<b>11:00 am</b>	<b>End Stage Liver Disease: Recap and Clinical Cases</b> <ul style="list-style-type: none"> <li>• A review of Pre-course lecture on end-stage liver disease</li> <li>• Complications of cirrhosis</li> <li>• Liver transplant in the era of DAA's</li> <li>• Clinical cases to illustrate HE, HRS and/or Thrombocytopenia</li> </ul>
<b>11:30 am</b>	<b>Hepatocellular Carcinoma(HCC) - Screening and Disease Progression</b> <ul style="list-style-type: none"> <li>• Screening diagnostic serum assays and imaging tests</li> <li>• Treatment and management options: Ablation, TACE and Surgery</li> <li>• New studies showing cost effectiveness of surveillance post SVR</li> <li>• PRIUS Study (MRI vs US) Abbreviated MRI</li> <li>• 2023 AASLD screening guidance for liver cancer</li> <li>• AASLD guidance is less critical of liver biopsy for cancer detection</li> </ul>
<b>12:00 pm</b>	<b>Hepatocellular Carcinoma: New Systemic Treatment Options</b> <ul style="list-style-type: none"> <li>• <b>A case-based approach to HCC treatment</b></li> <li>• Promising 1<sup>st</sup> and 2<sup>nd</sup> line therapies for liver cancer</li> <li>• New data on the benefit of downstaging</li> <li>• New chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC</li> <li>• Checkpoint inhibitors and VEGE inhibitors</li> </ul>
<b>12:35 pm</b>	<b>Luncheon and Product Information Session</b>
<b>1:05 pm</b>	<b>Dessert and View Exhibits</b>

<b>1:20 pm</b>	<p><b>Cholestatic Liver Disease: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis</b></p> <ul style="list-style-type: none"> <li>• Epidemiology of PSC and Ursodiol and Antibiotic Treatments</li> <li>• Predicting outcomes and Improving Survival in PSC patients</li> <li>• Causes and Markers of PBC</li> <li>• Coping with the clinical features of PBC</li> <li>• Ursodeoxycholic Acid (UDCA) and Obeticholic Acid</li> <li>• Highlights of the ELATIVE study on elafibranor and the ENHANCE study on seladelpar</li> </ul>
<b>2:05 pm</b>	<p><b>Alcohol Associated Liver Disease</b></p> <ul style="list-style-type: none"> <li>• The growing prevalence of alcohol over-consumption and its impact on liver health</li> <li>• Alcohol consumption and malnutrition</li> <li>• Warning signs and intervention in alcohol-associated hepatitis</li> <li>• Promising therapeutic agents for AAH</li> </ul>
<b>2:30 pm</b>	<b>Break &amp; View Exhibits</b>
<b>2:35 pm</b>	<p><b>Steatotic Liver Disease: The new healthcare epidemic</b></p> <ul style="list-style-type: none"> <li>• New naming conventions for fatty liver disease: MASLD and MASH– what and why?</li> <li>• Epidemiology, Demographics and Diagnosis</li> <li>• Scoring, Staging and Management of Metabolic Liver Disease</li> <li>• The ‘unhealthy’ rise in MASLD in the US population and What can be done</li> <li>• Treatment options for thrombocytopenia; including alternatives to platelet transfusion.</li> </ul>
<b>2:50 pm</b>	<p><b>MASH Treatments in Practice and in Development</b></p> <ul style="list-style-type: none"> <li>• Current therapies for NASH including Updates from AASLD and EASL</li> <li>• Lifestyle changes as a therapy</li> <li>• Drugs in clinical development for NASH – Semaglutide and Resmitemon</li> <li>• MASH Diagnosis and Treatment case</li> </ul>
<b>3:25 pm</b>	<p><b>Closing Comments, Post-test and Wrap-Up</b> Program adjourns at 4:15 pm</p>
<b>4:05 pm</b>	<p><b>Post- Lecture 3 - Fluid Management, Ascites and Hepatorenal Syndrome 30 minutes</b></p> <p><b>Post-Lecture 4 - Overcoming barriers to liver health in special populations - 40 minutes.</b></p> <p><b>Post-Lecture 5 – AASLD Update – Highlights of the 2023 Liver Meeting –40 min</b></p>

**Course Director: Paul J. Pockros, MD - Scripps Health**

**Peer Review: Tracy Ander, DO - University of Louisville School of Medicine**